NZ703167A - Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof - Google Patents

Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

Info

Publication number
NZ703167A
NZ703167A NZ703167A NZ70316713A NZ703167A NZ 703167 A NZ703167 A NZ 703167A NZ 703167 A NZ703167 A NZ 703167A NZ 70316713 A NZ70316713 A NZ 70316713A NZ 703167 A NZ703167 A NZ 703167A
Authority
NZ
New Zealand
Prior art keywords
compounds
cancer
medical conditions
disstituted
hepa
Prior art date
Application number
NZ703167A
Other languages
English (en)
Inventor
Charles Shih
Qian Shi
Hui-Kang Wang
Ching-Yuan Su
Original Assignee
Allianz Pharmascience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/525,941 external-priority patent/US8710272B2/en
Application filed by Allianz Pharmascience Ltd filed Critical Allianz Pharmascience Ltd
Publication of NZ703167A publication Critical patent/NZ703167A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ703167A 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof NZ703167A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/525,941 US8710272B2 (en) 2007-01-08 2012-06-18 Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
PCT/US2013/046138 WO2013192091A1 (en) 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

Publications (1)

Publication Number Publication Date
NZ703167A true NZ703167A (en) 2016-09-30

Family

ID=49769258

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ703167A NZ703167A (en) 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

Country Status (14)

Country Link
EP (3) EP3150203B1 (enExample)
JP (2) JP6392752B2 (enExample)
KR (1) KR102171469B1 (enExample)
CN (3) CN104755076A (enExample)
AU (1) AU2013277423B2 (enExample)
CA (1) CA2876957C (enExample)
DK (1) DK3150203T3 (enExample)
ES (1) ES2775173T3 (enExample)
HK (1) HK1211211A1 (enExample)
IN (1) IN2015MN00131A (enExample)
MX (1) MX2014015936A (enExample)
NZ (1) NZ703167A (enExample)
SG (1) SG11201408387YA (enExample)
WO (1) WO2013192091A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018273988C1 (en) 2017-05-26 2025-11-13 Bruin Biosciences, Inc. Chemoembolization agents
CN107226783B (zh) * 2017-06-20 2019-07-23 武汉工程大学 一种溶酶体靶向荧光探针及其制备方法
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
GB2572259B (en) * 2018-03-23 2022-03-30 Merry Life Biomedical Company Ltd Uses of curcumin derivative
JP2020125285A (ja) * 2019-01-04 2020-08-20 アリアンツ ファーマサイエンス リミテッド 神経変性性障害の治療方法
JP2020117489A (ja) * 2019-01-04 2020-08-06 アリアンツ ファーマサイエンス リミテッド 脳癌の治療方法
CN110183320B (zh) * 2019-04-15 2021-06-11 四川大学 一类多烯二酮类抗肿瘤化合物
JP7843545B2 (ja) * 2022-04-29 2026-04-10 南京邁諾威医薬科技有限公司 抗アンドロゲン受容体活性を有する化合物及びその使用
CN116120182A (zh) * 2023-02-16 2023-05-16 常州大学 姜黄素衍生物及其合成方法和在抗雄激素受体中的应用
CN116283676B (zh) * 2023-03-24 2025-03-28 常州大学 一种姜黄素衍生物及其制备方法和应用
CN122277382A (zh) * 2026-05-27 2026-06-26 兰州大学第一医院 一种姜黄素类似物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US812408A (en) 1905-08-19 1906-02-13 Roy Ernest Dickerson Educational device for teaching spherics.
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US7355081B2 (en) * 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
DK2104659T3 (en) * 2007-01-08 2015-11-02 Allianz Pharmascience Ltd Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
CA2694953C (en) * 2007-07-31 2015-12-01 Androscience Corporation Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
US20090282496A1 (en) * 2008-04-04 2009-11-12 University Of Rochester Medical Center Androgen Receptor Related Methods for Treating Bladder Cancer

Also Published As

Publication number Publication date
EP3549581A3 (en) 2020-02-19
AU2013277423B2 (en) 2018-08-09
JP6392752B2 (ja) 2018-09-19
EP3150203A1 (en) 2017-04-05
EP2861222A4 (en) 2015-08-05
EP2861222A1 (en) 2015-04-22
MX2014015936A (es) 2016-06-24
EP3150203B1 (en) 2020-02-19
JP2015520233A (ja) 2015-07-16
CN104755076A (zh) 2015-07-01
HK1211211A1 (en) 2016-05-20
SG11201408387YA (en) 2015-01-29
CA2876957C (en) 2021-02-16
JP2018135386A (ja) 2018-08-30
CA2876957A1 (en) 2013-12-27
CN110279680A (zh) 2019-09-27
KR102171469B1 (ko) 2020-10-30
ES2775173T3 (es) 2020-07-24
EP3549581A2 (en) 2019-10-09
KR20150023012A (ko) 2015-03-04
CN106220507A (zh) 2016-12-14
IN2015MN00131A (enExample) 2015-10-16
AU2013277423A1 (en) 2015-01-22
WO2013192091A1 (en) 2013-12-27
DK3150203T3 (da) 2020-04-14

Similar Documents

Publication Publication Date Title
MX2014015936A (es) Compuestos con andamio estructural de (1e,6e)-1,7-bis-(3-4-dimetox ifenil)- hepa-1,6-dieno-3,5-diona 4,4-disustituida -, su actividad biologica, y usos de los mismos.
Kanchi et al. Tocotrienols: the unsaturated sidekick shifting new paradigms in vitamin E therapeutics
JOP20200097A1 (ar) معدل مستقبل أندروجين واستخداماته
CY1120828T1 (el) Ρυθμιστης υποδοχεα ανδρογονων για τη θεραπευτικη αντιμετωπιση του καρκινου του προστατη και των σχετιζομενων νοσηματων με υποδοχεα ανδρογονων
MX2010002353A (es) Amidas heterociclicas utiles para tratamiento de cancer y psoriais.
MX2009007345A (es) Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo.
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
MY168791A (en) Carbamate compounds and of making and using same
WO2007125331A3 (en) Amino-ethyl-amino-aryl (aeaa) compounds and their use
MY162502A (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
PH12012500497A1 (en) Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
WO2010093727A8 (en) Quinazolinones as prolyl hydroxylase inhibitors
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
UA101393C2 (ru) КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ
WO2009066060A3 (en) 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
GEP20166450B (en) Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
WO2013040227A3 (en) Therapeutic compounds
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
WO2019199667A3 (en) Pladienolide compounds and their use
NZ715837A (en) 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
UA101168C2 (ru) 4-(тетразол-5-ил)хиназолиновые производные как противораковые средства

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3170855, SHIH, CHARLES, ANDROSCIENCE CORPORATION11175 FLINTKOTE AVE.SAN DIEGO, CALIFORNIA 92121, US; 3170856, SHI, QIAN, ANDROSCIENCE CORPORATION11175 FLINTKOTE AVE.SUITE FSAN DIEGO, CALIFORNIA 92121, US; 3170857, WANG, HUI-KANG, ANDROSCIENCE CORPORATION11175 FLINTKOTE AVE.SUITE FSAN DIEGO, CALIFORNIA 92121., US; 3470523, CHING-YUAN SU, 3721 BOULDER RIDGE DR, CHAMPAIGN, ILLINOUS 61822 , US

Effective date: 20150630

ASS Change of ownership

Owner name: ALLIANZ PHARMASCIENCE LIMITED, TW

Effective date: 20151126

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JUN 2018 BY CPA GLOBAL

Effective date: 20170601

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JUN 2019 BY CPA GLOBAL

Effective date: 20180524

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JUN 2020 BY CPA GLOBAL

Effective date: 20190501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JUN 2021 BY CPA GLOBAL

Effective date: 20200422

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JUN 2022 BY COMPUTER PACKAGES INC

Effective date: 20210530

ASS Change of ownership

Owner name: ANNJI PHARMACEUTICAL CO., LTD., TW

Effective date: 20211130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JUN 2023 BY COMPUTER PACKAGES INC

Effective date: 20220530

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JUN 2024 BY COMPUTER PACKAGES INC

Effective date: 20230530

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JUN 2025 BY COMPUTER PACKAGES INC

Effective date: 20240530

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JUN 2026 BY COMPUTER PACKAGES INC

Effective date: 20250530